These fact sheets lay out the health care landscape in every state, providing data on a variety of health care topics that may be the focus of policy debates in the 2024 election. Topics include health costs; women’s health policy, including state abortion, contraception and maternity laws and policies; health coverage, including the Affordable Care…
Research shows that between 2018 and 2022, industry-sponsored trials enrolled over eight times more patients than federally sponsored trials.
Goal is for patients to receive ‘seamless, comprehensive care, whether at the clinic or at home,’ said Tim Hembree, D.O., Ph.D., chief quality officer at Moffitt
By embracing available data, cutting-edge technology, and an intelligent marketplace, payers can design solutions that optimize costs across the entire healthcare ecosystem. The post Payers Possess the Tools to Tackle Rising Healthcare Costs appeared first on MedCity News.
A new model of virtual care is emerging that promises to better democratize healthcare access for millions of Americans and revamp our care delivery system with a focus on value and efficiency. The post Democratizing Access to Care: The Rise of Virtual Centers of Excellence appeared first on MedCity News.
This Health Policy 101 chapter explores LGBTQ+ people’s identities and demographics, their experiences with health and health care, including the significant disparities, and the related health policy landscape.
SACRAMENTO, Calif. — California voters are considering whether to roll back some of the criminal justice reforms enacted a decade ago as concerns about mass incarceration give way to public anger over property crime and a fentanyl crisis that has plagued the state since the covid-19 pandemic hit. Proposition 36, on the November ballot, would…
Federal officials resolved more than a decade ago to crack down on whopping government overpayments to private Medicare Advantage health insurance plans, which were siphoning off billions of tax dollars every year. But Centers for Medicare & Medicaid Services officials have yet to demand any refunds — and over the years the private insurance plans…
Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA-approved indication for the blockbuster drug. The post Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD appeared first on MedCity News.
Here is a selection of recent executive hires, retirements, promotions and layoffs occurring across the healthcare industry. The post Healthcare Moves: A Monthly Summary of Hires and Layoffs appeared first on MedCity News.